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Abstract 
Background: Recent studies have shown a decrease in annualized relapse rates (ARRs) in 
placebo groups of randomized controlled trials (RCTs) in relapsing multiple sclerosis (RMS).  
Methods: We conducted a systematic literature search of RCTs in RMS. Data on eligibility 
criteria and baseline characteristics were extracted and tested for significant trends over 
time. A meta-regression was conducted to estimate their contribution to the decrease of trial 
ARRs over time. 
Results: 56 studies were identified. Patient age at baseline (p<0.001), mean duration of MS 
at baseline (p=0.048), size of treatment groups (p=0.003), Oxford Quality Scale scores 
(p=0.021), and the number of eligibility criteria increased significantly (p<0.001), whereas 
pre-trial ARR (p=0.001), the time span over which pre-trial ARR was calculated (p<0.001), 
and the duration of placebo-controlled follow-up (p=0.006) decreased significantly over time. 
In meta-regression of trial placebo ARR the temporal trend was found to be insignificant, with 
major factors explaining the variation being pre-trial ARR, the number of years used to 
calculate pre-trial ARR, and study duration. 
Conclusion: The observed decline in trial ARRs may result from decreasing pre-trial ARRs 
and a shorter time period over which pre-trial ARRs were calculated. Increasing patient age 
and duration of illness may also contribute. 
Keywords: multiple sclerosis; relapses; annualized relapse rates; placebo; baseline 
characteristics; eligibility criteria; meta-analysis; meta-regression; systematic review 
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Introduction 
Relapsing MS (RMS) is defined by the presence of relapses, a neurological deterioration 
lasting greater than 24 hours with stabilization or recovery [1]. Relapses occur in relapsing-
remitting MS (RRMS), secondary progressive MS (SPMS) and progressive-relapsing MS 
(PRMS) [2]. The development of therapies that have successfully targeted relapses has 
meant that relapse focused outcome measures are common in RMS trials – of particular 
importance is the annualized relapse rate (ARR) [3, 4]. Recently, a downward trend in trial 
ARRs of placebo patients has been identified in randomized controlled trials (RCTs) [5, 6]. 
Although placebo patients receive no active agent, their ARRs improve significantly 
compared to baseline and increasingly so [7]. This trend is unexplained but has implications 
for inter-trial comparability of ARRs [6]. This is particularly important as more therapies are 
licensed in the absence of head-to-head data. We investigated possible reasons for this 
downward trend in trial placebo ARR over time by analyzing patient baseline characteristics, 
eligibility criteria and study design features in RCTs. 
 
Methods 
Systematic literature search 
A systematic literature search was conducted in PubMed, the Cochrane Library, and Web of 
Science aiming to identify placebo-controlled, double-blind RCTs in MS with data on trial 
ARR or, alternatively, data that allowed trial ARR to be calculated. We searched [July 13, 
2012] using combinations of the search terms „multiple sclerosis“, „ms“, „placebo“, 
„controlled“, „control“, „relapsing“, „remitting“, „relapse“, „exacerbation“, „lesion“, „reduction“, 
„rate“, „patients“, „double-blind“, and „clinical“. (see supplementary material). We excluded 
cross-over trials and studies where patients in the control group received add-on therapies.  
 
4 
 
Data extraction 
The following data were extracted by one reviewer and verified by another:  
 the trial ARR of the placebo group along with the associated number of placebo 
patients and the time period over which the ARR was calculated; 
 the number of eligibility criteria, words and characters used to describe the criteria; 
 trial inclusion criteria: age, pre-trial ARR and Expanded Disability Status Scale 
(EDSS) score at baseline; 
 trial inclusion criteria describing the minimum number of days since the last relapse or 
use of high-dose steroids; 
 patient baseline characteristics: age, pre-trial ARR, EDSS, and duration of MS; 
 the number of patients and the number of female patients; 
 the Oxford Quality Scale (OQS) score was calculated [8]. 
 
If possible, mean values were extracted along with standard deviations, or median values 
and interquartile ranges. Where standard deviations were not available, they were calculated 
from p-values, standard errors, confidence intervals or t-statistics [9]. If an ARR was not 
stated, it was calculated by dividing the total number of relapses by the number of patients in 
the placebo group, giving a mean relapse rate, and then extrapolating to an annualized 
relapse rate by correcting for the time over which relapses were observed. When an adjusted 
rate was given, i.e. adjusted to age, sex or other parameters, as well as an unadjusted rate, 
the latter was preferred. Whenever trials distinguished between different intensities of 
relapses, the total sum of relapses was counted irrespective of severity. For ARRs without a 
quoted standard error we derived errors based on a Poisson approximation. 
 
For our count of eligibility criteria, all inclusion criteria counted, unless they were mutually 
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exclusive, and all exclusion criteria were counted, unless they matched any inclusion criteria 
already counted, similar to the approach established by Clisant et al. [10]. Only criteria 
applying to patients with RMS counted. Having the correct diagnosis to be included to a 
study counted as one criterion. To determine the number of words or characters used to 
describe the eligibility criteria, all sentences or tables containing these criteria were copied 
into a text processing program (LibreOffice 3.5.2.2) and counted automatically. Features due 
to editing such as spaces and bullets were not included in the count. Captions of inclusion or 
exclusion criteria did count. When supplementary material offered more detailed information 
on eligibility criteria than the main publication, it was used instead of the latter. 
 
Baseline characteristics of patients with RMS for the placebo group and all patients were 
retrieved. Where possible, data on RRMS patients were preferred over data on patients with 
other forms of MS. When the mean age at baseline was not given, it was calculated by 
adding the mean MS duration to the mean age at the onset of the disease, if provided. When 
pre-trial ARR was not specified, but the number of relapses in a certain time period or a non-
annualized relapse rate, it was calculated as above. Whenever a study presented multiple 
pre-trial ARRs, calculated over different time periods, all were extracted. When baseline 
characteristics for the total patient group were not available, they were calculated by 
combining data provided for the individual treatment arms. Baseline characteristics of 
patients randomized to treatment arms were preferred over characteristics describing only 
patients that actually received treatment.  
 
When multiple pre-trial ARRs could be collected, those accounting for the longest period 
were used. In these cases, pre-trial ARRs of the same groups calculated over different time 
periods were compared. When inclusion criteria appeared in a complex context, allowing 
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alternative options to qualify in one measure or mutually exclusive options of different 
measures, items were omitted. 
 
Data analysis 
For the purpose of all analyses of temporal trends, the year and month of publication was 
used. When mean values were not given, available median values were used as a direct 
estimate instead, if they did not require further mathematical handling. Corresponding 
interquartile ranges, if not equal to zero, were used to estimate standard deviations, 
assuming normal distributions. Values obtained in such a manner were indicated in the 
figures. Mean values with standard deviations had top priority, mean values with standard 
deviations estimated from interquartile ranges second, median values with standard 
deviations estimated from interquartile ranges third priority, followed by solitary mean values 
and lastly solitary median values. 
 
The natural logarithms of the trial and pre-trial ARR of placebo groups were modeled by 
Gaussian linear regression weighted by the inverse standard error squared. For the 
predicted means 95% confidence intervals were calculated. For baseline characteristics 
(age, disease duration, EDSS score, gender distribution) we calculated linear regressions 
over time, weighted by the inverse standard error squared, taking all values with standard 
errors into account. We calculated (unweighted) linear regressions for the number of 
eligibility criteria, the number of words or characters used to describe these criteria, the 
minimum pre-trial ARR for inclusion, the number of years over which the pre-trial ARR was 
calculated, the minimum number of days before baseline without the use of high dose 
steroids, the minimum number of days without relapse, the duration of placebo-controlled 
follow-up in days, the number of treatment arms, the average number of patients in each 
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treatment arm, the score on the Oxford Quality Scale, and the patient years considered in its 
calculation. 
 
As supportive analyses, we compared the mean values of four deliberate partitions of the 56 
trials included in this study, testing for possible trends that might have been concealed in the 
analysis of all studies over time. We decided to subdivide the trials at recognizable points in 
trial history: The first cluster of trials comprised all trials up to the end of 1994, the second 
cluster all trials from the beginning of 1995 to the end of 2000, the third cluster all trials from 
the beginning of 2001 to the end of 2009, the fourth cluster all trials from the beginning of 
2010 to today. Below we refer to these analyses as epoch analyses. 
 
The logarithmic ratios of ARRs comparing the different pre-trial time periods were 
investigated via a random-effects meta-analysis with inverse variance weighting. The 
combined estimates are reported along with 95% confidence intervals (CIs) and p-values 
testing the null hypothesis of no difference between the time intervals. Heterogeneity 
between studies is estimated and reported in terms of the heterogeneity measure I2, which is 
the ratio of the between-trial variance and the total variance, alongside the p-values of the 
chi-square test of heterogeneity. Forest plots illustrating the ratios of the individual studies 
and the combined effect allow for visual comparison of the heterogeneity and provide an 
overview of the results. The meta-analysis was conducted using the RevMan 5.1 software 
(http://ims.cochrane.org/revman).  
 
Finally, all statistically significant temporal trends were investigated in a meta-regression 
calculating to what extent they contributed to the temporal trend in trial ARRs. The final 
combination of included variables was chosen in respect to the Bayesian information criterion 
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(BIC), allowing a model as simple as possible with as little as four variables, yet explaining 
the bulk of the downward trend in trial ARR. In all instances, the level of statistical 
significance was set at 5%. 
 
Results 
A total of 56 randomized, placebo-controlled trials (references given in the web appendix) 
were identified including 14,792 patients of which 5,380 had been randomized to placebo. 
The study duration was on average 12 months (range 3 to 60 months). The total follow-up 
was 23,157 patient-years including 8,696 patient-years on placebo. Table 1 gives an 
overview of the patient populations included in the 56 trials and further information is 
included in the web appendix (supplementary material). Trial ARRs in placebo patients 
decreased (Figure 1) by 4.5% per year (95% CI (3.2; 5.7); p<0.001). This confirms previous 
findings by Inusah et al. [5] and Nicholas et al. [6] who conducted their reviews on different 
although overlapping sets of studies. 
 
Temporal trends in pre-trial ARR and associated factors 
Pre-trial ARR decreased over the last 30 years by 2.0% per year (95% CI (1.3; 2.6); p<0.001, 
Figure 1). From 1982 to 2012, the number of years over which pre-trial ARR was calculated, 
decreased significantly by approximately 1.5 years (p<0.001). The minimum pre-trial ARR for 
inclusion did not change significantly over time. The required days prior to baseline without 
relapse or high-dose steroid use likewise did not change. Seven studies provided data on 
pre-trial ARRs calculated over one and two years (Figure 2). The ARRs in the second year 
before inclusion (months -13 to months -24) were reduced by 49% (95% CI (44%; 54%), 
p<0.001) compared to the year prior to the study (months -1 to -12).  
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Changes in other baseline characteristics over time 
We detected statistically significant trends over time in the following baseline characteristics. 
Baseline age increased by approximately one additional year for every five years (p<0.001), 
as did baseline MS duration, which increased by one additional year of MS duration every 
eight years (p=0.048, Figure 3). Baseline EDSS scores and minimum steroid-free time before 
inclusion in the trial were not found to be significant in the trend analyses (p=0.289 and 
p=0.059, respectively), but changes over time were found in the epoch analyses (p=0.003 
and p=0.02, respectively). The mean minimum number of steroid-free days is 68 days for the 
first cluster, 35 days for the second, 38 days for the third, and 32 days for the fourth cluster of 
trials. The mean baseline scores on the EDSS are 3.67 for the first cluster of trials, 2.47 for 
the second, 2.35 for the third, and 2.72 for the fourth. The percentages of female patients in 
trials did not change over time.  
 
Changing eligibility criteria and study design characteristics over time 
The number of eligibility criteria increased significantly by one criterion every 16 months 
(p<0.001). The number of words used in the description of these criteria increased by about 
7 words per year (p<0.001), as did the number of characters (about 40 characters per year, 
p<0.001). The duration of the placebo-controlled follow-up changed significantly with a 
shortening by 16 days of follow-up per year (p=0.006) and the number of patients in the 
placebo groups increased by 6.7 patients per year (p=0.004) on average. The number of 
patient–years (sample size × follow-up time) used to calculate the trial ARR increased, albeit 
non-significantly, over time with 8.5 additional patient years per annum (p=0.051). The 
number of treatment arms per trial increased significantly by nearly 1.5 over the last three 
decades (p<0.001), as did the average number of patients in each treatment arm (by 7.0 
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patients per year, p=0.003). Scores on the OQS slightly increased over time with, on 
average, studies scoring an additional point on the scale, which is scored out of five, every 
36 years (p=0.021).  
 
Explaining temporal trends in trial ARR 
The temporal trend line for the trial ARR shown in Figure 1 explains about 46% of the 
variation observed in trial ARR over the years (Figure 4, left column). To gain insights into 
the drivers of this trend we utilized meta-regression incorporating changes in patient 
populations and trial characteristics. After taking all possible combinations of variables into 
consideration, we included pre-trial ARR, the number of years used to calculate pre-trial 
ARR, study duration and mean baseline MS duration. For comparison with the simple model 
including the time trend only we also added the year of publication. In the resulting model 
explaining about 69% of the variation in trial ARR the temporal trend is insignificant with 
major contributors being pre-trial ARR, the number of years used to calculate pre-trial ARR, 
study duration, and MS duration (Figure 4, right column). 
 
Discussion 
The aim of this study was to explain the decrease in trial ARRs in placebo patients that has 
been demonstrated previously [5, 6]. We found it to decrease by 4.5% each year in this 
study. One possible cause is the observed decrease in pre-trial ARR by nearly 0.8 relapses 
per year over the last three decades. This, in turn, may be related to the increasing age and 
duration of MS of patients in the trials. Very recently pre-trial ARR and mean baseline age 
were independently identified as predictors for on-trial ARR in a smaller number (n=13) of 
phase III trials with at least 18 months follow-up by Stellmann et al. [11]. We noted an 
increase in patients’ average age over time; in our systematic review, patients were at 
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baseline on average approximately six years older at the end of our period of observation 
compared to the beginning of our observation period. Tremlett et al. found a reduction in 
ARRs by 17% for every 5 years of MS duration [12]. The increase in MS duration by 3.6 
years, as observed in our studies, could constitute a 13% decrease in ARRs. Considering 
this, in an older trial population with longer disease duration a decrease in pre-trial ARR with 
an associated decreasing trial ARR is to be expected. With EDSS scores remaining relatively 
stable after an early drop, especially in trials since 1995, this means that patients in newer 
studies tend to be later in their disease courses with less disability compared to patients in 
older studies. Thus they are likely to have less severe disease courses. However, one might 
speculate that longer disease durations might also reflect earlier diagnoses. The likely driver 
of these changes in study populations is the widening availability of increasingly effective 
treatment modifying those deemed suitable for trials by clinicians [5]. While the cause of 
temporal trends is most likely related to the patient recruitment period, this is not always 
available, and given the long-term nature of trends the publication dates should constitute a 
reasonable proxy. Besides changes in patient recruitment mechanisms, another potential 
factor might be the geographical region, but as studies are typically multi-center and often 
multi-national, this is among the questions that are beyond what can be addressed on the 
basis of the aggregate data. 
 
Another factor contributing to the decrease in trial ARRs is the reduced time period over 
which pre-trial ARRs had been calculated; this decreased on average by 1.5 years over the 
past three decades. Using shorter periods of time over which pre-trial ARRs are calculated 
might thereby allow trials to include patients who, if pre-trial ARR was assessed over a 
longer time span, might not have been eligible for trial inclusion. We suspect the shortening 
of the time period considered for the estimation of the pre-trial ARR to be a principal factor 
driving the regression to the mean effect that was previously described by Martínez-Yélamos 
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et al. [13] and Nicholas et al. [7], and that also appears to be evident in the findings of 
Kappos et al. [14]. The notion that patients are recruited into a study shortly after a flare up is 
supported by the finding that the ARR in the second year prior to recruitment is just half of 
the ARR in the year prior to the study. An increase in the number of phase III studies might 
also be a cause for the decrease in trial ARR – as phase III studies usually last longer than 
other studies, the longer duration may again contribute to a larger regression to the mean 
effect, and hence a larger discrepancy between trial and pre-trial ARR [7]. 
 
While growing numbers of eligibility criteria reflect the increasing understanding and 
complexity of possible influences on outcome variables such as the trial ARR, early trials with 
fewer eligibility criteria might have been more susceptible to such influences than modern 
ones. Similarly, changing definitions of MS and relapses, as well as varying forms of report, 
confirmation and treatment in case of relapses undoubtedly play a role, as has been 
suggested by Inusah et al. [7]. The Oxford Quality Scale scores of the trials in RMS generally 
increased over time – reflecting higher trial quality or better reporting as described [15]. 
 
Since the relative incidence of MS in women compared to men has risen from 2:1 to 4:1 over 
recent years [16], we were surprised to find stability in the proportion of patients who were 
women. Held et al. showed a correlation between on-study relapse rates and female sex [17] 
and therefore changes in the gender ratio over time could potentially explain part of the 
temporal trends in trial ARR.  
 
According to our meta-regression the temporal trend observed by Inusah et al. [5] and 
Nicholas et al. [6] becomes relatively insignificant and other changes explain about 60% of 
the variation in the trial ARR. Similar analyses, aiming at modelling the pre-trial ARR, or 
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excluding the pre-trial ARR from the set of predictors, yield comparable R² values using 
different sets of explanatory variables with age, number of eligibility criteria and number of 
patients being among the influential variables in addition. While the use of many partly 
correlated variables, the range of which is partly determined by what may be elicited from the 
investigated studies, and any model selection approach employed may have their issues, it is 
obvious that a range of possibly relevant factors are related to the observed decline in 
relapse rates. When trying to establish a causal relationship, the (a priori) plausibility should 
eventually also come into consideration. This understanding will allow us to make rational 
comparisons of therapeutic effects as increasing numbers of therapies for RMS emerge. In 
particular, this highlights the importance of considering certain variables, like population 
characteristics, pre-trial ARR and the particularities of its measurement already in the design 
of studies as well as when reporting and interpreting study results. 
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Table 1: Baseline characteristics of all randomized patients and the placebo groups in 
the 56 randomized, controlled trials included in the systematic review. 
 
  Placebo patients  All randomized 
patients 
 N Median (range) N Median (range) 
Number of patients 55 54 (7 - 556) 55 148 (13-1644) 
Percentage female 47 68.1 (41.2 - 82.9) 48 69.6 (52.6-82.8) 
Mean age (years) 46 36.7 (26.5 – 43.0) 46 36.0 (27.7 – 43.6) 
Mean MS duration 
(years) 
40 7.2 (2.1 – 11.0) 40 7.1 (2.6 – 11.7) 
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Figure 1: Pre-trial annualized relapse rate (ARR) and on-trial placebo ARR observed in 
the 56 trials identified by our literature search against the calendar year in which the 
papers were published. The size of the circles indicates the size of the trial and is 
inversely proportional to the standard error of the ARR. The solid lines show the 
model values and the dashed lines indicate 95% confidence intervals. 
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Figure 2: Rate ratio of ARRs calculated for the year before inclusion and the year 
before that for trials reporting ARR for 12 and 24 months prior to the study. 
 
 
 
IV: Inverse variance weights; CI: Confidence interval; SE: Standard error 
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Figure 3: Mean duration of illness of placebo patients in years, weighted by the 
inverse standard error squared. Whiskers indicate the doubled standard error, if 
available. The linear fit takes into account all values with standard errors – the 
remaining items are colored grey. 
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Figure 4: Factors driving the temporal trend in placebo ARR and their importance. Left 
column: The temporal trend line for the (logarithmic) trial ARR shown in Figure 1 explains 
about 46% of the observed variation in trial ARR over the years. Right column: The Meta-
regression explains about 69% of the variation in trial ARR; the temporal trend is insignificant 
with major contributors being pre-trial ARR, the number of years used to calculate pre-trial 
ARR, study duration, and MS duration. 
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WEB APPENDIX 
Literature search 
Our systematic literature search resulted in the identification of the 56 randomized, placebo-
controlled trials in relapsing multiple sclerosis reported in the following publications (in order 
of publication): 
[A1] Gonsette RE, Demonty L, Delmotte P et al. Modulation of immunity in multiple 
sclerosis: a double-blind levamisole-placebo controlled study in 85 patients. J. Neurol. 
1982; 228: 65-72. 
[A2] Mertin J, Rudge P, Kremer M et al. Double-blind controlled trial of 
immunosuppression in the treatment of multiple sclerosis: final report. The Lancet 
1982; 320: 351-354. 
[A3] Camenga DL, Johnson KP, Alter M et al. Systemic recombinant alpha-2 
interferon therapy in relapsing multiple sclerosis. Archives of Neurology 1986; 43: 
1238. 
[A4] Jacobs L, Salazar AM, Herndon R et al. Intrathecally Administered Natural 
Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis. Archives 
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of Neurology 1987; 44: 589-595. 
[A5] Jacobs L, Salazar AM, Herndon R et al. Multicentre double-blind study of 
effect of intrathecally administered natural human fibroblast interferon on 
exacerbations in multiple sclerosis. The Lancet 1986; 328: 1411-1413. 
[A6] Hirsch RL, Johnson KP, Camenga DL. The placebo effect during a double 
blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: 
immunological and clinical findings. International Journal of Neuroscience 1988; 39: 
189-196. 
[A7] Milanese C, La Mantia L, Salmaggi A et al. Double blind controlled 
randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results. 
The Italian Journal of Neurological Sciences 1988; 9: 53-57. 
[A8] Goodkin DE, Bailly RC, Teetzen ML et al. The efficacy of azathioprine in 
relapsing-remitting multiple sclerosis. Neurology 1991; 41: 20. 
[A9] Bastianello S, Pozzilli C, D'Andrea F et al. A controlled trial of mitoxantrone in 
multiple sclerosis: serial MRI evaluation at one year. The Canadian Journal of 
Neurological Sciences 1994; 21: 266-270. 
[A10] Durelli L, Bongioanni MR, Cavallo R et al. Chronic systemic high-dose 
recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease 
activity, and lymphocyte interferon gamma production in relapsing-remitting multiple 
sclerosis. Neurology 1994; 44: 406-413. 
[A11] The IFNB Multiple Sclerosis Study Group and The University of British 
Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple 
sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-
1285. 
[A12] The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in 
relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-661. 
[A13] Andersen O, Lycke J, Tollesson PO et al. Linomide reduces the rate of active 
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lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900. 
[A14] Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for 
disease progression in relapsing multiple sclerosis. The Multiple Sclerosis 
Collaborative Research Group (MSCRG). Annals of Neurology 1996; 39: 285-294. 
[A15] Lycke J, Svennerholm B, Hjelmquist E et al. Acyclovir treatment of relapsing-
remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. 
Journal of Neurology 1996; 243: 214-224. 
[A16] Fazekas F, Deisenhammer F, Strasser-Fuchs S et al. Randomised placebo-
controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting 
multiple sclerosis. The Lancet 1997; 349: 589-593. 
[A17] Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial 
of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI 
outcome. Journal of Neurology 1997; 244: 153-159. 
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Table A1: Sizes and durations of the individual studies considered here. 
study duration (years) total patients placebo patients 
[A1] Gonsette, R. E. et al. (1982) 2.00   
[A2] Mertin, J. et al. (1982) 1.25 43 22 
[A3] Camenga, D. L. et al. (1986) 1.00 98 50 
[A4,A5] Jacobs, L. et al. (1987) 2.00 69 35 
[A6] Hirsch, R. L. et al. (1988) 1.00 98 50 
[A7] Milanese, C. et al. (1988) 3.00 13 7 
[A8] Goodkin, D. E. et al. (1991) 2.00 54 25 
[A9] Bastianello, S. et al. (1994) 1.00 25 12 
[A10] Durelli, L. et al. (1994) 0.50 20 8 
[A11,A12] IFNB (1995) 5.00 372 123 
[A13] Andersen, O. et al. (1996) 0.46 28 14 
[A14] Jacobs, L. D. et al. (1996) 2.99 301 143 
[A15] Lycke, J. et al. (1996) 2.00 60 30 
[A16] Fazekas, F. et al. (1997) 2.00 148 73 
[A17] Millefiorini, E. et al. (1997) 2.00 51 24 
[A18] Miller, A. E. et al. (1997) 0.50 103 54 
[A19,A20] Van Oosten, B. W. et al. (1997) 1.50 71 36 
[A21] Achiron, A. et al. (1998) 2.00 40 20 
[A22,A23] Johnson, K. P. et al. (1998) 2.92 251 126 
[A24] Noseworthy, J. H. et al. (1998) 3.00 151 79 
[A25] PRISMS (1998) 2.00 560 187 
[A26] Deisenhammer, F. et al. (1999) 2.00 148 73 
[A27] Lenercept (1999) 0.46 168 44 
[A28] Myhr, K. M. et al. (1999) 0.50 97 33 
[A29] OWIMS (1999) 0.92 293 100 
[A30] Patti, F. et al. (1999) 2.00 58 29 
[A31] Romine, J. S. et al. (1999) 1.50 52 25 
[A32] Tubridy, N. et al. (1999) 0.46 72 35 
[A33] Brod, S. A. et al. (2001) 0.75 29 10 
[A34] Comi, G. et al. (2001) 0.75 239 120 
[A35] Bech, E. et al. (2002) 0.46 70 34 
[A36] Lewanska, M. et al. (2002) 1.00 49 17 
[A37] Miller, D. H. et al. (2003) 0.50 213 71 
[A38] Wroe, S. J. (2005) 0.25 98 33 
[A39] Filippi, M. et al. (2006) 1.07 1644 548 
[A40] Kappos, L. et al. (2006) 0.50 277 92 
[A41] O'Connor, P. W. et al. (2006) 0.69 179 61 
[A42] Polman, C. H. et al. (2006) 2.30 942 315 
[A43] Broadley, S. A. et al. (2008) 0.23 50 11 
[A44] Comi, G. et al. (2008) 0.69 306 102 
[A45] Fazekas, F. et al. (2008) 0.92 127 41 
[A46] Garren, H. et al. (2008) 0.92 267 87 
[A47] Hauser, S. L. et al. (2008) 0.92 104 35 
[A48] Kappos, L. et al. (2008) 0.46 256 65 
[A49] Mostert, J. P. et al. (2008) 0.46 38 19 
[A50] Segal, B. M. et al. (2008) 0.71 249 49 
[A51] Barkhof, F. et al. (2010) 1.00 292 100 
[A52] Giovannoni, G. et al. (2010) 1.84 1326 437 
[A53] Kappos, L. et al. (2010) 2.00 1272 418 
[A54] Vollmer, T. L. et al. (2010) 0.46 215 69 
[A55,A56] De Stefano, L. et al. (2011) 0.31 180 60 
[A57] Kappos, L. et al. (2011) 0.46 218 54 
[A58] O'Connor, P. et al. (2011) 2.07 1088 363 
[A59] Comi, G. et al. (2012) 2.00 1106 556 
 10 
 
[A60] Miller, D. H. et al. (2012) 0.46 343 99 
[A61] Saida, T. et al. (2012) 0.50 171 57 
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Table A2: Results of regression analyses to check for time trends in individual 
variables. The percentage of trials for which the corresponding data are available is 
shown, as well as the value , confidence interval and p-value for the regression 
coefficient indicating the yearly change. 
Variable 
available 
data 
p-value coefficient 
95% confidence 
interval 
trial ARR* 100% <0.001 -0.032 [-0.042, -0.022] 
log (trial ARR)* 100% <0.001 -0.046 [-0.059, -0.032] 
number of years used to calculate pre-trial ARR  75% <0.001 -0.049 [-0.071, -0.027] 
minimum ARR at inclusion 86% 0.581 0.003 [-0.008, 0.013] 
minimum relapse-free days at inclusion 55% 0.247 -0.623 [-1.701, 0.456] 
minimum steroid-free days at inclusion 68% 0.059 -0.991 [-2.019, 0.038] 
minimum EDSS at inclusion 95% 0.051 -0.028 [-0.056, 0.000] 
maximum EDSS at inclusion 95% 0.986 -0.0003 [-0.036, 0.035] 
eligibility criteria: number 100% <0.001 0.771 [0.392, 1.151] 
eligibility criteria: words 100% <0.001 6.651 [3.372, 9.930] 
eligibility criteria: characters 100% <0.001 39.638 [20.109, 59.168] 
Oxford quality scale 100% 0.021 0.028 [0.004, 0.051] 
baseline age (years)* 82% <0.001 0.198 [0.098, 0.299] 
pre-trial ARR* 73% <0.001 -0.027 [-0.039, -0.015] 
log(pre-trial ARR)* 73% 0.097 -0.020 [-0.044, 0.004] 
baseline EDSS* 79% 0.289 0.011 [-0.010, 0.031] 
baseline MS duration (years)* 82% 0.048 0.122 [0.001, 0.243] 
baseline number of patients 98% 0.004 6.664 [2.270, 11.059] 
percentage of females* 84% 0.337 -0.122 [-0.004, 0.001] 
study duration (years) 100% 0.006 -0.043 [-0.074, -0.013] 
patient-years 98% 0.060 8.853 [-0.386, 18.092] 
number of treatment arms 100% <0.001 0.048 [0.027, 0.069] 
mean number of patients per treatment arm 98% 0.003 7.028 [2.426, 11.630] 
* weighted linear regression (based on standard errors) 
statistically significant (p < 0.05) 
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Table A3: Results of the sub-group analysis; shown is the estimated mean and 
standard error for each variable within the given cluster of studies as defined by 
period of publication. The p-values indicate whether there is a significant difference 
among clusters. 
Variable p-value 
Cluster I 
(...-1994) 
Cluster II 
(1995-2000) 
Cluster III 
(2001-2009) 
Cluster IV 
(2010-...) 
trial ARR* <0.001 1.15 (0.34) 1.29 (0.14) 0.76 (0.14) 0.42 (0.03) 
log(trial ARR)* <0.001 0.29 (0.33) 0.29 (0.13) -0.17 (0.22) -0.70 (0.09) 
 number of years used to calculate 
pre-trial ARR 
0.008 2.21 (0.20) 1.97 (0.13) 1.42 (0.16) 1.50 (0.24) 
minimum ARR at inclusion 0.824 1.00 (0.10) 1.00 (0.06) 0.96 (0.07) 1.07 (0.09) 
minimum relapse-free days at 
inclusion 
0.341 60.9 (12.5) 38.2 (5.6) 39.2 (4.9) 34.3 (7.2) 
minimum steroid-free days at 
inclusion 
0.020 68.5 (9.5) 35.5 (5.1) 38.4 (5.3) 31.6 (7.2) 
minimum EDSS at inclusion 0.107 0.67 (0.29) 0.63 (0.16) 0.17 (0.17) 0.10 (0.23) 
maximum EDSS at inclusion 0.269 6.00 (0.36) 5.24 (0.20) 5.47 (0.21) 5.70 (0.28) 
eligibility criteria: number 0.004 8.9 (3.8) 13.8 (2.6) 18.9 (2.7) 27.3 (3.6) 
eligibility criteria: words 0.002 82 (32) 126 (22) 158 (23) 253 (30) 
eligibility criteria: characters 0.002 459 (190) 711 (131) 894 (135) 1486 (181) 
Oxford quality scale 0.291 4.00 (0.23) 4.42 (0.16) 4.44 (0.16) 4.60 (0.22) 
baseline age (years)* 0.004 32.0 (2.3) 35.4 (0.6) 36.5 (0.5) 38.0 (0.5) 
pre-trial ARR* 0.001 1.57 (0.26) 1.47 (0.08) 1.20 (0.07) 1.06 (0.05) 
log(pre-trial ARR)* 0.014 0.50 (0.24) 0.48 (0.08) 0.02 (0.10) 0.20 (0.19) 
baseline EDSS* 0.004 3.67 (0.48) 2.47 (0.10) 2.35 (0.09) 2.72 (0.08) 
baseline MS duration (years)* 0.007 5.84 (1.73) 5.15 (0.61) 5.45 (0.64) 8.15 (0.61) 
baseline number of patients 0.002 52 (114) 159 (74) 285 (76) 621 (102) 
percentage of females* 0.340 65.6 (4.8) 72.1 (1.5) 69.7 (1.4) 69.2 (1.1) 
study duration (years) 0.004 1.53 (0.29) 1.80 (0.20) 0.75 (0.20) 1.11 (0.27) 
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patient-years 0.018 36 (86) 147 (56) 104 (57) 375 (77) 
number of treatment arms 0.001 2.00 (0.21) 2.32 (0.14) 2.83 (0.15) 3.00 (0.20) 
mean number of patients per 
treatment arm 
0.005 26 (44) 66 (28) 106 (29) 224 (39) 
* weighted linear regression (based on standard errors) 
statistically significant (p < 0.05) 
 
